Before 1989, the only diagnostic tests available for the detection of hepatitis viruses were for hepatitis A virus, hepatitis B virus (HBV), and hepatitis D virus. At that time, it had already been recognized that, in a significant proportion of patients with acute and chronic hepatitis, no viral pathogen could be identified. However, the clinical presentations in these patients were similar to those in patients with viral hepatitis, and several lines of evidence indicated that the diseases were transmissible. These patients were thus referred to as having "non-A, non-B hepatitis" [1] . Owing to the advancement of molecular biology technology, hepatitis C virus (HCV) and hepatitis E virus were subsequently discovered as the major pathogens of parenteral and enteric non-A, non-B hepatitis, respectively [2] . At present, the etiologic agent can be determined in Ͼ95% of patients with chronic viral hepatitis. However, in the remaining small portion of patients with chronic hepatitis, the cause remains unknown. In a study conducted in the United States, no definite cause could be found in 4.9% of patients with chronic hepatitis or cirrhosis, and these cases were termed "cryptogenic" [3] . Approximately half of these patients had received blood transfusions, suggesting a viral etiology. In another study, enhanced HLA expression in liver samples from patients with chronic non-A-C hepatitis was documented, also supporting a viral etiology [4] . Furthermore, therapeutic trials using interferon (IFN)-␣ to treat chronic non-A-C hepatitis resulted in a response rate of ϳ50%, arguing for a viral pathogen [5] .
For acute hepatitis, the proportion of patients with undetermined causes is even higher. Previously in Taiwan, we found that 15.9% of inpatients with acute hepatitis had non-A-E hepatitis [6] . Additionally, 9.7% of patients with fulminant hepatitis were categorized as having non-A-E hepatitis [7] . Collectively, it can be deduced that unrecognized viral pathogens are still responsible for ϳ5% of chronic hepatitis cases and for at least 15% of acute hepatitis cases. In light of these observations, scientists have sought to identify the theoretically existing hepatitis viruses. As a result, several new viruses have been discovered, including GB virus C (GBV-C), TT virus (TTV), and SEN virus (SENV) [8 -10] . Although the discoveries of these viruses are highly significant in the field of molecular virology, ep-idemiological data have failed to verify a causative role for these viruses in human hepatitis. The most striking finding arguing against their roles in hepatitis is that these viruses infect a high percentage of healthy individuals who do not have hepatitis. Furthermore, at least one study has argued that GBV-C is in fact not a hepatotropic virus [8] .
In a recent study, we discovered a novel hepatotropic viruslike agent, NV-F, associated with human non-A-E hepatitis [11] . Initial studies elucidated its physical and chemical properties, including its size (Ͻ0.2 m in diameter), the buoyant densities of the NV-F-associated particles (1.33-1.39 and 1.22-1.25 g/mL), and the sensitivity of the NV-F DNA fragment to S1 nuclease digestion. As determined by a polymerase chain reaction (PCR)-based assay, 17 (24.6%) of 69 patients with non-A-E hepatitis had detectable NV-F DNA in their serum samples, compared with only 5 (2.8%) of 180 healthy individuals. Notably, the NV-F agent was detected in 1 patient with fulminant non-A-E hepatitis. Furthermore, immunofluorescence analysis using an antibody developed against a peptide synthesized according to the putative open reading frame revealed the presence of NV-F antigen in the hepatocytes of infected patients.
Subsequently, by means of a PCR-based quantitative assay, the NV-F DNA concentration was measured in patients with chronic hepatitis B or C [12] . The median serum NV-F DNA concentration was below the detection limit (1.2 ϫ 10 5 copies/ mL) for patients with chronic hepatitis B, compared with a median serum NV-F concentration of 9.3 ϫ 10 5 copies/mL for patients with chronic hepatitis C. In patients with chronic hepatitis B, a reciprocal relationship was found between serum NV-F DNA and HBV DNA concentrations, indicating the likelihood of interference between these 2 agents. Another study showed that NV-F DNA was identified in 12 (15.4%) of 78 patients with hepatocellular carcinoma [13] . In contrast, only 1 (1.3%) of the 78 age-and sex-matched control subjects was positive for NV-F DNA (odds ratio, 13.8; P ϭ .001). Patients with hepatoma who had NV-F infection were significantly older (by 9 years) than those without NV-F infection.
Although initial data support a role for NV-F in human hepatitis, further clinical investigation is needed before it can be called a hepatitis virus. In the present study, we took advantage of the fact that apprioximately one-third of patients with chronic HCV infection in Taiwan are positive for serum NV-F DNA and examined clinicopathological parameters and therapeutic responses in these patients.
METHODS
Patients, serology, and IFN treatment. This study, conducted from January 2002 to January 2003, included 101 consecutive patients receiving a 6-month (24-week) course of antiviral therapy prescribed at the Chang Gung Medical Center; all patients provided informed consent. All patients were positive for antibody against HCV (anti-HCV) and were negative for HBV surface antigen (HBsAg), HBV DNA, and HIV. Patients were excluded if they had other causes of chronic liver diseases, such as alcoholic hepatitis (alcohol intake exceeding Ͼ80 g/d), autoimmune hepatitis, hemochromatosis, Wilson disease, and primary biliary cirrhosis, or a history of decompensated cirrhosis or hepatocellular carcinoma.
Documented data included patient sex; age; pretherapy aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels; body mass index; total bilirubin, ␣-fetoprotein (AFP), and albumin levels; leukocyte counts; serum HCV RNA levels; genotypes; Knodell histological activity index (HAI) values [14] ; periportal, intralobular, portal inflammation, and fibrosis scores; and histological appearance of fatty metamorphosis. Serum samples were collected at the time of pretherapeutic liver biopsy, during the therapeutic course, at the end of treatment, and 6 months later. All samples were stored at Ϫ70°C until testing.
PegIFN-␣2a (PEGASYS; 180 g) was given weekly for 24 weeks. Ribavirin (1200 mg) was given daily for the first 4 weeks. Thereafter, the dosage was adjusted individually according to the hemoglobin concentration (800 -1200 mg/day). All patients received a 24-week course of treatment. Patients were followed up for at least 24 weeks after the end of treatment.
Anti-HCV was assayed with a standard enzyme immunoassay kit (HCV-II; Abbott Laboratories), and HBsAg was assayed with a radioimmunoassay kit (Ausria-II RIA; Abbott Laboratories). HCV RNA was quantified using the COBAS Amplicor HCV monitor test (version 2.0; Roche Diagnostics; detection limit, 1.44 ϫ 10 3 copies/mL). The HCV RNA qualitative test was performed using the COBAS Amplicor HCV RNA test (Roche; detection limit, 1.2 ϫ 10 2 copies/mL). HCV genotypes were determined using the INNO-LiPA HCV II assay (Innogenetics). HBV DNA was detected with the COBAS Amplicor HBV Monitor test (Roche; detection limit, 2 ϫ 10 2 copies/mL).
For comparison, 123 outpatients who visited our liver clinics because of general malaise and who were negative for anti-HCV, HBsAg, HBV DNA, and antibody against HIV were also included. These patients did not have any of the other causes of chronic liver disease detailed above. Patients with fatty liver were not excluded from this study.
Detection of NV-F DNA. Serum (100 L) was mixed with 300 L of buffer (13.3 mmol/L Tris-HCl [pH 8 .00], 6.7 mmol/L EDTA, 0.67% sodium dodecyl sulfate, and 133 g/mL proteinase K) and incubated at 55°C for 4 h. Two phenol-chloroform extractions were followed by 1 chloroform extraction, and DNA was precipitated with cold ethanol. The precipitate was dissolved in 20 L of TE buffer (10 mmol/L Tris-HCl [pH 8.0] and 1 mmol/L EDTA). PCR was performed in 100 L of a mixture containing 10 L of DNA, 2 U of Super Tag (HT Biotechnology), 200 mol/L deoxynucleotide triphosphate, 100 pmol of each primer, and the provided reaction buffer. The primers were 5'-TGTTGGTGGCACAAAGCCCC-3' and 5'-CTTTGTGG-TCTCGCTCTCTC-3' for the first-step PCR and 5'-GCAA-AGTTGGCAACCCCCGC-3' and 5'-CTCCAGGCCCGGAG-CAGAAG-3' for the second-step PCR. The reaction was allowed to proceed at 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min in each cycle. The amplification was done for 25 cycles in a DNA thermal cycler (PerkinElmer Cetus). Two steps of PCR (nested) were performed. A serum sample obtained from a healthy individual (negative for NV-F DNA) and an aliquot of pure water were included in each batch as negative controls. A sample positive for NV-F DNA was used as a positive control [11] . To avoid false-positive or false-negative results, all assays were performed independently twice by 2 technicians at separate benches. By use of a set of serially diluted samples with known NV-F DNA concentrations [12] , the detection limit of the PCR assay was found to be 50 copies/mL.
Immunohistochemical analysis. Liver specimens were fixed in 10% formaldehyde and embedded in paraffin. The histopathological findings were evaluated and numerically scored according to the HAI. Scores were assessed independently by 2 observers without knowledge of the clinical data. Fivemicrometer paraffin sections were mounted on poly-L-lysinecoated slides for immunohistochemistry. After deparaffinization in xylene, the sections were rehydrated through graded ethanol. Hepatocyte expression of the NV-F antigen was assessed by the avidin-biotin immunoperoxidase method. The sections were incubated in PBS (0.1 mol/L [pH 7.4]) containing 5% hydrogen peroxide for 15 min and were subsequently washed twice (5 min each) in PBS containing 0.025% Triton X-100 (Sigma Chemical). The tissue sections were then incubated with 3% bovine serum albumin and 10% normal goat serum for 30 min, followed by a 1:500 dilution of rabbit polyclonal antibody against the NV-F antigen at 37°C for 1 h. The methods used to generate the NV-F antigen and antibody have been described elsewhere [11] . After being washed with PBS, sections were subsequently incubated with a 1:400 dilution of biotinconjugated goat anti-rabbit immunoglobulins (Jackson Immunoresearch) for 40 min. After being rinsed with PBS, sections were treated with avidin-biotin complex (Vectastain Elite ABC Kit; Vector Laboratories) for 30 min, and the reaction products were visualized in diaminobenzidine solution (Vector Laboratories). Counterstaining was performed using hematoxylin. Antibody-absorption experiments were performed by preincubation of the antibody with the NV-F antigen (20 g/L antibody) at 4°C overnight.
Statistical analysis. Results were calculated as means Ϯ SDs or as medians and ranges for nonparametric data. Analysis was conducted using the t test, the Mann-Whitney U tests, or the 2 test with Yates' correction, as appropriate. All statistical testing was 2-tailed at the 5% level. The statistical analysis was done with the help of SPSS software (version 13.0; SPSS).
RESULTS
Comparison of the clinicopathological data between HCVinfected patients with and those without serum NV-F DNA. Of the 101 patients included in this study, 30 were positive for serum NV-F DNA, and 71 were negative. The clinicopathological parameters were compared between these 2 groups of patients (table 1) . Patients positive for the NV-F agent had significantly higher levels of serum aminotransferases. Median AST levels were 124.5 versus 69 U/L (P Ͻ .001), and median ALT levels were 205.5 versus 110 U/L (P Ͻ .001). Consistent with these findings, significantly higher serum AFP levels were also noted in patients who were positive for serum NV-F DNA (mean Ϯ SD, 19.7 Ϯ 23.2 vs. 9.3 Ϯ 14.5 ng/mL; P ϭ .014). Mean albumin levels were slightly lower in NV-F-positive patients, although this difference did not reach statistical significance (4.35 Ϯ 0.31 vs. 4.60 Ϯ 0.38 g/dL; P ϭ .081). Histological analysis revealed that patients who were positive for serum NV-F DNA had significantly higher HAI scores (median, 9.5 vs. 7; P Ͻ .001). When individual categories of scores were examined, the periportal necrosis, intralobular inflammation, portal inflammation, and fibrosis scores were all significantly higher in patients who were positive for serum NV-F DNA (P Ͻ .05), indicating more severe hepatitis activity.
To better understand the relationship between the NV-F agent and serum aminotransferase levels, patients were categorized according to those levels (table 2). These data indicated that, among patients with ALT levels Ͼ8-fold the upper limit of normal, 80% were positive for serum NV-F DNA, whereas, among patients with ALT levels Ͻ2-fold the upper limit of normal, only 14.8% were positive. Similarly, among patients with AST levels Ͼ4-fold the upper limit of normal, 72.2% were positive for serum NV-F DNA, whereas, among patients with AST levels Ͻ2-fold the upper limit of normal, only 17.8% were positive.
Categorical analysis according to HAI score was also performed (table 2) . Among patients with HAI scores 10, 51.7% were positive for serum NV-F DNA, whereas, among patients with HAI scores 5, only 6.7% were positive.
Immunohistochemical analysis. To demonstrate the specificity of the immunohistochemical analysis, antibody-absorption testing was performed. It showed that positive staining for tissue NV-F antigen could be inhibited by preincubation of the anti-NV-F antibody with NV-F antigen ( figure 1A ). All liver biopsy tissue samples were subjected to immunohistochemical analysis. Of the 30 patients who were positive for serum NV-F DNA, 14 showed positive liver expression of tissue NV-F antigen, compared with none of the patients who were negative for serum NV-F DNA. Heterogeneous mosaic distribution of the tissue NV-F antigen was the most frequently observed pattern ( figure  1B and 1C) , occurring in 8 of the 14 patients. Other patterns included increased NV-F antigen expression in a cirrhotic nod-ule ( figure 2A ), a few scattered NV-F-positive hepatocytes in tissue (figure 2B), increased numbers of NV-F-positive hepatocytes in the periportal areas ( figure 2C and 2D) , clustering of the NV-F-positive hepatocytes with enlarged sinusoid spaces (figure 2E, left) , and trapped NV-F-positive hepatocytes in inflammatory and fibrotic cells ( figure 2E, right) . Focal necrosis or piecemeal necrosis with gathering of inflammatory cells was observed in some areas next to the NV-F-positive cells. Western blot analysis was performed using 10 NV-F-positive and 10 NV-F-negative biopsy samples (figure 3). A positive band at 35 kDa was found only in the NV-F-positive samples. A second band at 36 kDa was also noted in some NV-F-positive samples.
Responses to antiviral therapy. All patients received 6 months of pegIFN and ribavirin antiviral therapy. Owing to our national health insurance policy, only a 6-month course of therapy was provided regardless of viral genotype. The virological responses for HCV were evaluated at the end of therapy (EOT) as well as 6 months later (sustained virological response [SVR] ). No significant difference in EOT responses and SVRs was found between patients who were positive and those who were negative for serum NV-F DNA. In this study, 29 (96.7%) of 30 NV-Fpositive patients and 62 (87.3%) of 71 NV-F-negative patients achieved EOT responses (P Ͼ .9); 20 (66.7%) of 30 NV-F-positive patients and 50 (70.4%) of 71 NV-F-negative patients achieved SVRs (P ϭ .814). Because HCV genotype is a major determinant of therapeutic response after antiviral treatment, we examined the influence of HCV genotype in both NV-F NOTE. Data are the no. of patients positive for NV-F per the total no. of patients in the respective category.
a Categorized on the basis of the fold increase relative to the upper limit of normal.
DNA-positive and NV-F DNA-negative groups (table 3) . Among patients who were positive for NV-F DNA, the rate of SVR of HCV clearance was not significantly different between patients with genotype 1 and those with genotype non-1. In contrast, among patients who were negative for NV-F DNA, the rate of SVR was significantly higher among patients with genotype non-1 (P ϭ .008). In Taiwan, genotype non-1 includes genotypes 2 and 3 only.
Finally, NV-F DNA was assayed again at the EOT time point and 6 months later. Of the 30 patients who were positive for serum NV-F DNA, 27 (90%) had negative results, and all 27 remained negative for serum NV-F DNA 6 months after the EOT.
Association between serum NV-F DNA and hepatitis. To determine whether infection with NV-F alone could be associated with hepatitis activity, we studied 123 outpatients who requested liver function evaluation at our liver clinic because of general malaise with no known cause. Patients with fatty liver were not excluded. Of these 123 patients, 17 (13.8%) were positive for serum NV-F DNA (group 1), and 106 (86.2%) were negative (group 2). In groups 1 and 2, proportions of male patients were 9 (52.9%) of 17 and 71 (67.0%) of 106, respectively (P ϭ .282); mean Ϯ SD ages were 46.8 Ϯ 12.0 and 54.0 Ϯ 13.0 years (P ϭ .034); median AST levels were 72 (range, 17-1686) and 34 (range, 12-300) U/L (P ϭ .011, MannWhitney U test); and median ALT levels were 122 (range, 15-1038) and 41 (range, 8 -512) U/L (P ϭ .003, Mann-Whitney U test).
DISCUSSION
Although several new viruses, including TTV, hepatitis G virus, and SENV, have been proposed to represent new hepatitis viruses, clinicopathological evidence correlating these viruses with hepatitis activity is lacking. We have recently identified a new viruslike agent, NV-F, whose prevalence differed substantially between healthy individuals and patients with non-A-E hepatitis (2.8% vs. 24.6%). Importantly, NV-F was shown to be hepatotropic. In the present study, we provide biochemical as well as histological evidence showing that serum NV-F DNA positivity in patients with chronic HCV infection is associated with more severe hepatitis activity. Chronic HCV infection is generally associated with mild hepatitis activity. In some patients, however, severe exacerbations are occasionally observed. It is generally believed that fluctuations in HCV replication levels and/or host immune activities are the major causes of hepatitis flares. In the present study, we discovered that, among patients with ALT levels Ͼ8-fold the upper limit of normal, 80% were positive for serum NV-F DNA, suggesting that NV-F may play an important role in severe hepatitis exacerbations in chronic HCV infection in Taiwan. This hypothesis is strongly supported by our histological findings. However, it is still unknown whether NV-F in- The rate of SVR did not appear to be affected by the presence of the NV-F agent. This observation can be explained by the fact that NV-F DNA did not persist in the bloodstream for a long time in patients receiving IFN therapy. It is possible that NV-F can be easily eradicated by IFN-based therapy or, alternatively, that most NV-F infections are transient infections from which patients recover spontaneously. To address the latter possibility, a control group without any antiviral treatment would need to be evaluated longitudinally. The present data encourage IFNbased treatment in patients with chronic HCV infection who are also positive for serum NV-F DNA, to prevent severe hepatitis activity.
When HCV genotype was taken into consideration, we found that, among patients who were positive for serum NV-F DNA, the favorable therapeutic response among patients with genotype non-1 disappeared, indicating that coinfection with NV-F may interfere with the therapeutic responses in this subgroup. Notably, among all patients with genotype non-1 HCV infection, NV-F DNA positivity was associated with a lower rate of SVR, although the difference was not statistically significant (69.2% vs. 92.0%; P ϭ .154). A larger study population may be needed to determine whether this finding is authentic. This information is of particular importance in countries where genotype non-1 is dominant.
In summary, we have discovered that the presence of serum NV-F DNA in patients with chronic HCV infection is associated with more severe hepatitis activity. Overall, the presence of the NV-F agent did not affect the outcome of IFN-based antiviral therapy. Serum NV-F DNA did not persist for a long period in 4 -7) but not in the NV-F-negative samples (lanes 1-3) . Nonspecific signals were found in all samples (arrowheads). Hybridization with anti-␤-actin antibody was used as a protein-loading control (lower panel). patients receiving IFN-based antiviral therapy. This study supports the view that the NV-F agent plays a role in viral hepatitis.
